Axsome Therapeutics (AXSM) vs. Neurocrine Biosciences (NBIX): Is Faster Growth Worth Paying More For?
Axsome Therapeutics, Inc. (NASDAQ:AXSM) and Neurocrine Biosciences, Inc.
Axsome Therapeutics Inc. (AXSM)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Iridian Asset Management David Cohen And Harold Levy | 45,129 | $8,321,336 | -6% | 3.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $127.40 | 488 | $62,171.20 | 48,212 | 2025-09-08 | Filing | |
| $127.30 | 287 | $36,535.10 | 47,724 | 2025-09-08 | Filing | |
| $127.20 | 800 | $101,760.00 | 47,437 | 2025-09-08 | Filing | |
| $37.30 | 3,950 | $147,350.01 | 120,756 | 2021-11-19 | Filing | |
| $35.20 | 142 | $4,998.40 | 142 | 2021-11-18 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $208.65 | 10,000 | $2,086,500.00 | 0 | 2026-09-03 | Filing | |
| $213.95 | 4,660 | $997,007.00 | 7,229 | 2026-08-06 | Filing | |
| $212.01 | 45,004 | $9,541,298.04 | 7,229 | 2026-08-05 | Filing | |
| $240.25 | 49,666 | $11,932,256.50 | 7,229 | 2026-07-01 | Filing | |
| $249.12 | 286 | $71,248.32 | 58,367 | 2026-06-11 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 250,805 | $46,245,934 | 0.04% | |
| 2. | 62,384 | $11,502,986 | 0.2% | |
| 3. | 51,245 | $9,449,066 | 0.05% | |
| 4. | 44,070 | $8,126,067 | 0.54% | |
| 5. | 43,963 | $8,106,338 | 0.58% |
News See All
Why Baird Sees Growth Potential in Axsome Therapeutics, Inc. (AXSM)
Baird Equity Asset Management recently released its "Small/Mid Cap Growth Strategy" second-quarter 2026 investor letter. A copy of the letter can be downloaded here.
These Are the Stocks Reporting Earnings Today – August 10, 2026
Here’s a look at today’s key earnings reports from major publicly traded companies. Stock market investors will undoubtedly be watching closely for...
Axsome Therapeutics (AXSM) Stock is Attractive on the Back of its Key Drug
ClearBridge Investments, a global equity manager, recently published second-quarter 2026 commentary for its “Small Cap Growth Strategy”. A copy of the letter can be downloaded here.
10 Best Under-the-Radar Stocks to Invest In
In this article, we will discuss: 10 Best Under-the-Radar Stocks to Invest In.
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2026 Earnings Call Transcript
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2026 Earnings Call Transcript May 4, 2026Axsome Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.26 EPS, expectations were $-0.85.
Axsome Therapeutics, Inc. (AXSM): A Bull Case Theory
We came across a bullish thesis on Axsome Therapeutics, Inc. on X.com by @MoneyShow. In this article, we will summarize the bulls’ thesis on AXSM.
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q4 2025 Earnings Call Transcript
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q4 2025 Earnings Call Transcript February 23, 2026Axsome Therapeutics, Inc. misses on earnings expectations.
Axsome Therapeutics (AXSM) Reports 66% Revenue Growth in FY2025, Beats Analyst Estimates
Axsome Therapeutics Inc. (NASDAQ:AXSM) ranks among the mid-cap stocks to buy according to top investors. On January 20, H.C. Wainwright boosted its price target for Axsome Therapeutics Inc.
Top Investors' Stock Portfolio: 10 Mid-cap Stocks To Buy
In this article, we will take a look at 10 mid-cap stocks to buy according to top investors. The Fed's change from higher interest rates to rate cuts has caused what Amy Y.
Hedge Fund Resource Center